https://www.selleckchem.com/products/triapine.html 242, P<0.01), and positively correlated with age (r=0.353, P<0.001), and HDL-C (r=0.310, P<0.001). ENOX1 expression was positively correlated with WBC (r=0.244, P<0.01), INR (r=0.177, P<0.05), and gensini score (r=0.201, P<0.05). Multiple linear regression showed that creatinine, ALT, glucose and kallistatin are independent predictors for gensini score. Kallistatin had the highest diagnostic significance (P=0.007) when the AUC was 0.636, with a sensitivity of 0.735 and a specificity of 0.495. Expression of kallistatin was decreased in CHD patients and ENOX1 was increased in ACS patients. Kallistatin and ENOX1 were closely connected with the severity of CHD and kallistatin may be helpful in the diagnosis of CHD. Expression of kallistatin was decreased in CHD patients and ENOX1 was increased in ACS patients. Kallistatin and ENOX1 were closely connected with the severity of CHD and kallistatin may be helpful in the diagnosis of CHD. Functional hepatic reserve is important when considering sequential tyrosine kinase inhibitor (TKI) therapy for patients with advanced hepatocellular carcinoma (HCC). We assessed albumin-bilirubin (ALBI) score and Child-Pugh class as indices of liver function during sorafenib and lenvatinib treatment. A total of 212 patients with advanced HCC and Child-Pugh class A status who initiated TKI treatment at our hospital were enrolled in this retrospective cohort study. A total of 74 of the 212 patients underwent blood testing before starting sorafenib treatment and every 2 months after treatment initiation. In 74 patients, the median ALBI score before TKI treatment was -2.53, and after 2, 4, and 6 months it was -2.45, -2.44, and -2.36, respectively. ALBI scores tended to increase during TKI therapy. Among patients who experienced a time to progression ≤3.8 months, ALBI scores had increased 2 months after treatment initiation, and at 4 and 6 months, significant differences were observed (p < 0.01